Outsourcing Pharma
DECEMBER 13, 2021
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
pharmaphorum
DECEMBER 13, 2021
UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor (FcRn) antibody rozanolixizumab for autoimmune disease generalised myasthenia gravis (gMG), setting up regulatory filings next year. The MycarinG study met its primary endpoint, demonstrating a “statistically significant and clinically meaningful” improvement from baseline in the myasthenia gravis-activities of daily living (MG-ADL) score, said the Belgian drugmaker.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
DECEMBER 13, 2021
The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.
Fierce Healthcare
DECEMBER 13, 2021
Insurtech platform HealthCare.com banks $180M, boosts valuation to $1B. rtorrence. Mon, 12/13/2021 - 15:15.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
DECEMBER 13, 2021
A pair of trials have suggested that CAR-T therapies could offer an improved option for patients with large B cell lymphoma (LBCL) who have relapsed after or haven’t responded to first-line treatment. The results of the ZUMA-7 and TRANSFORM trials, reported at the American Society of Haematology (ASH) congress, could see Gilead Sciences’ Yescarta (axicabtagene ciloleucel) and Bristol-Myers Squibb’s Breyanzi (lisocabtagene maraleucel) move up the treatment pathway for this type
Fierce Healthcare
DECEMBER 13, 2021
Quartet picks up InnovaTel Telepsychiatry to expand its reach in the digital mental health market. hlandi. Mon, 12/13/2021 - 16:51.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
DECEMBER 13, 2021
Senate version of Build Back Better axes DSH cuts to hospitals in non-expansion states. rking. Mon, 12/13/2021 - 10:47.
Roots Analysis
DECEMBER 13, 2021
Earlier, approaches used for blood collection were invasive, time consuming and needed a healthcare expert. However, in recent years, the methods for blood collection are evolving at a rapid pace. According to research study, 69% of participant were found to take part more likely in clinical trials, if they are able to provide self-collected sample (at-home blood collection).
Fierce Healthcare
DECEMBER 13, 2021
Centene mulls divestiture of $2B international business as part of value creation effort. pminemyer. Mon, 12/13/2021 - 13:31.
pharmaphorum
DECEMBER 13, 2021
The UK government has said it will step up its COVID-19 booster vaccination dramatically, with everyone in England aged over 18 offered a third dose before the end of the month. Westminster has promised additional support for the devolved administrations in Scotland, Wales and Northern Ireland to step up the booster campaign, and Scotland has already said it intends to match England’s target.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Healthcare
DECEMBER 13, 2021
Employer insurance costs jumped in 2021—and the future is murky. pminemyer. Mon, 12/13/2021 - 11:46.
pharmaphorum
DECEMBER 13, 2021
A cloud-based tuberculosis screening programme for rural communities in India, developed by UK company Feedback, is being supported by a cash injection from online retail giant Amazon. Amazon Web Services (AWS) is providing funding to a pilot study of Feedback’s platform, which gathers X-ray images and uploads them to the cloud for remote assessment using artificial intelligence (AI) algorithms as well as clinical staff.
Pharma Times
DECEMBER 13, 2021
A team at The Institute of Cancer Research (ICR), London and the Clinical Trials Research Unit (CTRU) at the University of Leeds adopted a new high-speed trial methodology.
pharmaphorum
DECEMBER 13, 2021
Servier has revealed the full data from its phase 3 trial of Tibsovo as a first-line treatment for acute myeloid leukaemia that it teased in the summer, and the results look good with a big impact recorded on patient survival. The AGILE trial, which compared the combination of Tibsovo (ivosidenib) and Bristol-Myers Squibb’s chemotherapy Vidaza (azacitidine) to Vidaza plus placebo as a first-line therapy for IDH1-positive AML, showed a three-fold improvement in overall survival.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
DECEMBER 13, 2021
The approval from the European Commission (EC) is based on the results of five clinical studies, involving over 2,800 patients.
pharmaphorum
DECEMBER 13, 2021
It started with two Covid-19 vaccines – 2021 is the year interest in mRNA therapeutics boomed, reports Katrina Megget. The Covid-19 pandemic showed what could be done with resources and collaboration to accelerate the development of vaccines. One of its other scientific legacies was the specific development and approval of mRNA vaccines, the first in that drug class on the market.
Expert insights. Personalized for you.
142 
Let's personalize your content